

# High-Efficiency Particulate Air Filters in the Era of COVID-19: Function and Efficacy

David A. Christopherson<sup>1</sup>, William C. Yao, MD<sup>2</sup>,  
 Mingming Lu, PhD<sup>3</sup>, R. Vijayakumar, PhD<sup>4</sup>,  
 and Ahmad R. Sedaghat, MD, PhD<sup>1</sup>

Otolaryngology–  
 Head and Neck Surgery  
 2020, Vol. 163(6) 1153–1155  
 © American Academy of  
 Otolaryngology–Head and Neck  
 Surgery Foundation 2020  
 Reprints and permission:  
[sagepub.com/journalsPermissions.nav](http://sagepub.com/journalsPermissions.nav)  
 DOI: 10.1177/0194599820941838  
<http://otojournal.org>



## Abstract

Aerosol-generating procedures in the office represent a major concern for health care–associated infection of patients and health care providers by SARS-CoV-2, the causative agent for coronavirus disease 2019 (COVID-19). Although the Centers for Disease Control and Prevention has not yet provided any recommendations for the use of portable air purifiers, air purifiers with high-efficiency particulate air (HEPA) filters have been discussed as an adjunctive means for decontamination of SARS-CoV-2 aerosols in health care settings. This commentary discusses HEPA filter mechanisms of action, decontamination time based on efficiency and flow rate, theoretical application to SARS-CoV-2, and limitations. HEPA filter functionality and prior guidance from the Centers for Disease Control and Prevention for SARS-CoV-1 suggest theoretical efficacy for HEPA filters to decontaminate airborne SARS-CoV-2, although direct studies for SARS-CoV-2 have not been performed. Any portable HEPA purifier utilization for SARS-CoV-2 should be considered an adjunctive infection control measure and undertaken with knowledge of HEPA filter functionality and limitations in mind.

## Keywords

high-efficiency particulate air filter, HEPA, air purifier, coronavirus, COVID-19, SARS-CoV-2

Received May 25, 2020; accepted May 29, 2020.

Airborne transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19), occurs through respiratory droplets (generally  $>5 \mu\text{m}$ ) and aerosol droplets (generally  $<5 \mu\text{m}$ ) that are expectorated from the respiratory tracts of infected individuals.<sup>1</sup> Aerosol-generating procedures (AGPs) represent a major concern for health care–associated infection of patients and health care providers. As compared with large droplets, which are rapidly pulled downward by gravity, aerosols may remain suspended in the air for an hour or more.<sup>2</sup> Otolaryngology is one medical specialty at particularly high risk of health care–associated infection with SARS-CoV-2 due to

commonplace performance of AGPs in the office. Current guidance by the Centers for Disease Control and Prevention (CDC) is that AGPs be performed in airborne infection isolation rooms (ie, negative-pressure rooms) when possible; otherwise, procedure rooms should remain unoccupied until SARS-CoV-2-laden aerosols may be cleared through other means, such as room air exchanges from indwelling ventilation.<sup>3</sup> The CDC has not provided any recommendations for the use of portable air purifiers. Nevertheless, air purifiers with high-efficiency particulate air (HEPA) filters have been discussed as an adjunctive means for decontamination of SARS-CoV-2 aerosols in health care settings. Consideration of portable air purifiers with HEPA filters (HEPA purifiers) during the SARS-CoV-2 pandemic should be with extensive knowledge about the functionality, efficacy, and limitations of HEPA purifiers.

## Discussion

### Mechanisms of Action

HEPA filters are usually manufactured by pleating microfiber glass or other fibrous media made with multiple layers of randomly arranged fibers, with diameters ranging from 2 to 500 nm.<sup>4</sup> As air flows through the filter and in between the fibers, airborne particles—such as respiratory and aerosol droplets—will be trapped by 1 of 3 mechanisms: impaction, interception, and diffusion (**Figure 1**).<sup>5</sup> Adhesion to filter fibers may occur through Van der Waals forces, electrostatic attraction, and capillary action. For particle sizes  $>1 \mu\text{m}$ , impaction and interception are the most significant

<sup>1</sup>Department of Otolaryngology–Head and Neck Surgery, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA

<sup>2</sup>Department of Otorhinolaryngology–Head and Neck Surgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA


<sup>3</sup>Department of Chemical and Environmental Engineering, College of Engineering and Applied Sciences, University of Cincinnati, Cincinnati, Ohio, USA

<sup>4</sup>Aerfil LLC, Liverpool, New York, USA

### Corresponding Author:

Ahmad R. Sedaghat, MD, PhD, Department of Otolaryngology–Head and Neck Surgery, College of Medicine, University of Cincinnati, Medical Sciences Building Room 6410, 231 Albert Sabin Way, Cincinnati, OH 45267-0528, USA.

Email: [ahmad.sedaghat@uc.edu](mailto:ahmad.sedaghat@uc.edu)



**Figure 1.** Schematic of filtration mechanisms of impaction, interception, and diffusion. © R. Vijayakumar, reproduced with permission.


mechanisms of filtration, whereas diffusion is the dominant mechanism for trapping particles  $<0.1 \mu\text{m}$ .<sup>4</sup> Particles between  $0.1$  and  $1 \mu\text{m}$  are influenced by all 3 methods of capture to a lesser degree than those larger or smaller, which leads to a lower efficiency of filtration.<sup>4</sup>

### Efficacy

To qualify as HEPA grade, filters must remove at least 99.97% of all particles that are  $0.15$  to  $0.2 \mu\text{m}$ , for which HEPA filters are least effective. Thus, HEPA filters have at least 99.97% efficiency for removing all particles, with even higher efficiencies for particles both larger and smaller than  $0.15 \mu\text{m}$  (**Figure 2**). The interesting U-shaped efficiency curve of all HEPA filters, which has a minimum at  $0.15 \mu\text{m}$ , is due to the relative effectiveness of the 3 mechanisms of particle capture at various sizes. Filters with efficiencies  $>99.99\%$  are also termed ultralow penetration air filters.

### Clean Air Delivery Rate

HEPA purifiers of various sizes and power will remove particles at different rates. The clean air delivery rate (CADR) is an important performance parameter created by the Association of Home Appliance Manufacturers to quantify the cubic feet per minute of air completely filtered of a particle by the air purifier. The CADR is calculated as flow of air through the filtration system multiplied by the efficiency of filtration of the particular particle. CADR score is specific to particle sizes and typically reported for 3 categories of particle sizes: pollen ( $2.5$ - $80 \mu\text{m}$ ), dust ( $1$ - $30 \mu\text{m}$ ), and tobacco



**Figure 2.** High-efficiency particulate air filter efficiency as a function of particle size and filtration mechanism. MPPS, most penetrating particle size. © R. Vijayakumar, reproduced with permission.

smoke ( $0.1$ - $1 \mu\text{m}$ ).<sup>6</sup> The CADR for dust and tobacco smoke may be most useful for determining filtration rate of aerosols and viruses, respectively, which are generally in the corresponding size range.

A previously reported study by the Environmental Protection Agency illustrates practical considerations for airborne particle decontamination by HEPA purifiers.<sup>2</sup> Based on the assumption of complete mixing of the air during filtration, which was found to be a realistic approximation, the amount of time needed to filter a certain fraction of particles out of a volume of air was derived using the CADR:

$$C(t) = C_0 e^{-\left(\frac{\text{CADR}}{V}\right)t},$$

where  $C(t)$  is the concentration of the particle as a function of time,  $C_0$  is the initial particle concentration,  $V$  is the volume of the air being filtered, and  $t$  is time.<sup>2</sup> Therefore, a HEPA purifier that has a CADR score of 300 for tobacco smoke—indicating that the device removes all tobacco smoke particles from 300 cubic feet of air every minute—would be expected to clear 99% of all tobacco smoke particles in a 1000 cubic-foot room (eg,  $10 \times 10 \times 10$  ft) in 15 minutes. Location of HEPA purifier placement within the room and presence of basic furniture, such as a desk and chair, did not substantially affect efficacy, although pointing the purifier's air intake toward the particle source improved decontamination.<sup>2</sup>

### HEPA Filters Applied to SARS-CoV-2

The majority of aerosols that may be produced by human cough are  $<1 \mu\text{m}$ ,<sup>7</sup> and the SARS-CoV-2 virion is reported to be  $60$  to  $140$  nm ( $0.06$ - $0.14 \mu\text{m}$ ).<sup>1</sup> Although the CDC has recommended the use of HEPA filters in powered air-purifying respirators for effective filtration of SARS-CoV-

2,<sup>8</sup> at present the CDC has not provided any recommendations for the use of portable HEPA purifiers for decontamination of SARS-CoV-2 in clinical areas or procedure rooms. The US Food and Drug Administration recommends that manufacturers of air purifiers intended for use related to SARS-CoV-2 evaluate effectiveness against a representative virus.<sup>9</sup> Coincidentally, the CDC previously suggested the use of portable HEPA purifiers as an adjunctive infection control strategy for SARS-CoV-1, the causative agent of the 2003 SARS outbreak.<sup>10</sup>

### Considerations for Commercial Acquisition of HEPA Purifiers

Consumers are cautioned that commercially available air purifiers make claims with labels such as true HEPA, HEPA like, and HEPA type. However, to be labeled HEPA, a filter is required to be tested and individually certified according to standards by the US Institute of Environmental Sciences and Technology (IEST-RP-CC001.6) or the International Organization for Standardization (ISO 29463). Very few air purifiers meet this requirement. By comparison, CADR rating is a more reliable performance parameter. Medical HEPA air purifiers may additionally claim to have an ultraviolet light or other decontaminating agent to kill microbes that deposit on the filter itself. In most cases, their microbicidal effectiveness has not been independently verified. Manufacturer guidelines should be followed for when to change filters, as saturation of filters affects efficiency. Finally, proper personal protective equipment should be worn to exchange air purifier filters, as these filters may contain trapped SARS-CoV-2. Proper disposal procedures should be followed to avoid contamination.

### Conclusion

At present, there are no formal recommendations by the CDC for use of portable HEPA purifiers for decontamination of airborne SARS-CoV-2. Knowledge of HEPA filter functionality and prior CDC guidance for SARS-CoV-1 suggests theoretical efficacy for HEPA filters to remove airborne SARS-CoV-2, although it is important to emphasize that direct studies for SARS-CoV-2 have not been performed. Any utilization of portable HEPA purifiers for SARS-CoV-2 should be considered an adjunctive infection control measure and be undertaken with knowledge of HEPA filter functionality and limitations in mind.

### Author Contributions

**David A. Christopherson**, manuscript design/organization, drafting and revisions, final approval; **William C. Yao**, manuscript drafting/revisions, final approval; **Mingming Lu**, manuscript drafting/revisions, final approval; **R. Vijayakumar**, manuscript drafting/revisions, final approval; **Ahmad R. Sedaghat**, manuscript conception/design/organization, drafting and revisions, final approval.

### Disclosures

**Competing interests:** R. Vijayakumar is consultant in chief at the consulting firm Aerfil, LLC, and he has served on and chaired committees on HEPA standards at the US Institute of Environmental Sciences and Technology as well as the International Organization for Standardization. William C. Yao serves as a consultant for Stryker and is part of the speakers' bureau for OptiNose US, Inc.

**Sponsorships:** None.

**Funding source:** None.

### References

1. Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. *PLoS Pathog.* 2020;16:e1008536.
2. Kogan V, Harto C, Hesse DJ, Hofacre KC. Final report on evaluation of in-room particulate matter air filtration devices. Environmental Protection Agency. Published 2008. [https://cfpub.epa.gov/si/si\\_public\\_record\\_report.cfm?Lab=NHSRC&subject=Homeland%2520Security%2520Research&dirEntryId=188372](https://cfpub.epa.gov/si/si_public_record_report.cfm?Lab=NHSRC&subject=Homeland%2520Security%2520Research&dirEntryId=188372)
3. Centers for Disease Control and Prevention. Appendix B. Air: guidance for environmental infection control in health-care facilities. Published July 22, 2019. Accessed May 22, 2020. <https://www.cdc.gov/infectioncontrol/guidelines/environmental/appendix/air.html>
4. Perry JL, Agui JH, Vijaykumar R. *Submicron and Nanoparticulate Matter Removal by HEPA-Rated Media Filters and Packed Beds of Granular Materials*. Marshall Space Flight Center; 2016.
5. First MW. HEPA filters. *J Am Biol Safety Assoc.* 1998;3:33-42.
6. Sahu SK, Tiwari M, Bhangare RC, Pandit GG. Particle size distribution of mainstream and exhaled cigarette smoke and predictive deposition in human respiratory tract. *Aerosol Air Qual Res.* 2013;13:324-332.
7. Lindsley WG, Pearce TA, Hudnall JB, et al. Quantity and size distribution of cough-generated aerosol particles produced by influenza patients during and after illness. *J Occup Environ Hyg.* 2012;9:443-449.
8. Centers for Disease Control and Prevention. Considerations for optimizing the supply of powered air-purifying respirators (PAPRs): for healthcare practitioners (HCP). Published April 19, 2020. Accessed May 22, 2020. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/powered-air-purifying-respirators-strategy.html>
9. US Food and Drug Administration. Enforcement policy for sterilizers, disinfectant devices, and air purifiers during the coronavirus disease 2019 (COVID-19) public health emergency: guidance for industry and Food and Drug Administration staff. Published March 2020. <https://www.fda.gov/media/136533/download>
10. Centers for Disease Control and Prevention. III. Infection control in healthcare facilities: public health guidance for community-level preparedness and response to severe acute respiratory syndrome (SARS). Published May 3, 2005. Accessed May 22, 2020. <https://www.cdc.gov/sars/guidance/i-infection/healthcare.html>